2022 started off on some good notes for BaseLaunch, with two new companies (one still in stealth) joining our portfolio and another one announcing the start of their First-in-Human Clinical Trial.
But before jumping into the new year, here are some highlights from 2021:
- Our portfolio companies have collectively raised over $390M (and more to come soon so stay tuned!), with one of them – Anaveon – closing the largest financing round in 2021 of all Swiss biotech companies and another one – Alentis– also high on the list of biggest biotech venture rounds. Overall, from the 8 Swiss biotech companies in Switzerland`s top 20 venture financing rounds last year, half of them are located in the BaselArea, with two of them being Anaveon and Alentis. Read the full Venture Capital report here.
- We strengthened our ties to the global pharma industry adding China Medical Systems as a partner, joining the ranks of Roche, Pureos Bioventures, Roivant Sciences, Bridge Biotherapeutics, CSL Behring, and Johnson & Johnson;
- 4 new biotech ventures have been welcomed to our portfolio.
With 4 new ventures in 2021, 1 more in January and one soon to be announced, our portfolio keeps expanding in size and breadth of therapeutic areas and modalities. Counting on the steady, exceptional growth of Venture Capital investments in Switzerland and Europe, BaseLaunch is ready to set new records!
Interested in joining our portfolio? Submit your application before April 25th. And if you are in doubt whether your project may be too early, just reach out – it is never too early to get in touch with us!
Do not miss the full updates on our portfolio companies, partners, financing rounds, and upcoming events in our newsletter.